Freeline Therapeutics Holdings (DB:78F0) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

78F0 Panoramica delle azioni

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.

Informazioni sull'azienda

78F0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Trading at 30.7% below our estimate of its fair value

Revenue is forecast to grow 60.35% per year

Analisi del rischio

Makes less than USD$1m in revenue ($0)

Shares are highly illiquid

Has less than 1 year of cash runway

Does not have a meaningful market cap (€18M)

+ 1 più rischio

Freeline Therapeutics Holdings plc Concorrenti

Medigene

XTRA:MDG1

€31.0m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€60.4m

4SC

DB:VSC

€56.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Freeline Therapeutics Holdings
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.23
Massimo di 52 settimane	US$13.95
Minimo di 52 settimane	US$3.12
Beta	0.71
1Variazione di 1 mese	0%
Variazione a 3 mesi	-92.93%
Variazione di 1 anno	-98.23%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-99.85%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	78F0	DE Biotechs	DE Mercato
7D	0%	2.2%	-1.9%
1Y	-98.2%	-9.6%	12.3%

Ritorno vs Industria: 78F0 underperformed the German Biotechs industry which returned -23.1% over the past year.

Rendimento vs Mercato: 78F0 underperformed the German Market which returned 5.9% over the past year.

Volatilità dei prezzi

Is 78F0's price volatile compared to industry and market?
78F0 volatility
78F0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.7%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 78F0's share price has been volatile over the past 3 months.

Volatilità nel tempo: Insufficient data to determine 78F0's volatility change over the past year.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2015	152	Michael Parini	www.freeline.life

Freeline Therapeutics Holdings plc Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Freeline Therapeutics Holdings con la sua capitalizzazione di mercato?
78F0 statistiche fondamentali
Capitalizzazione di mercato	€16.41m
Guadagni(TTM)	-€55.72m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.3x

Rapporto P/E

78F0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
78F0 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$61.07m
Guadagni	-US$61.07m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-14.06
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato 78F0 nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

78F0 Panoramica delle azioni

Premi

Analisi del rischio

Freeline Therapeutics Holdings plc Concorrenti

XTRA:MDG1

€31.0m

XTRA:CNW

€6.5m

XTRA:2INV

€60.4m

DB:VSC

€56.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Recent updates

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Freeline Therapeutics Holdings plc Riepilogo dei fondamenti

0.0x

-0.3x

Guadagni e ricavi